<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67214">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02002039</url>
  </required_header>
  <id_info>
    <org_study_id>Erythropoietin 01</org_study_id>
    <nct_id>NCT02002039</nct_id>
  </id_info>
  <brief_title>Neuroprotective Role of Erythropoietin in Perinatal Asphyxia</brief_title>
  <official_title>Erythropoietin in Perinatal Asphyxia: A Randomized Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheri Kashmir Institute of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheri Kashmir Institute of Medical Sciences</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whether Erythropoietin improves the neurological outcomes of neonates with perinatal
      asphyxia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Death and or disability at 12-18 months of life</measure>
    <time_frame>12-18 months after birth</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Neurological outcomes including cerebral palsy, any gross motor delay, Hearing impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gross motor delay</measure>
    <time_frame>12-18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Hearing impairment</measure>
    <time_frame>12-18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Perinatal Asphyxia</condition>
  <arm_group>
    <arm_group_label>erythropoietin, perinatal asphyxia,</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline, perinatal asphyxia</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline on alternate days for 5 doses starting from first 6 hours of life</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>500 units /kg /day every other day for 5 doses</description>
    <arm_group_label>erythropoietin, perinatal asphyxia,</arm_group_label>
    <arm_group_label>Normal saline, perinatal asphyxia</arm_group_label>
    <other_name>erhthropoietin beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Babies with severe perinatal asphyxia with moderate to severe HIE in the immediate
             neonatal period

        Exclusion Criteria:

          -  Babies with congenital malformations

          -  Small for gestational age babies

          -  Babies with chromosomal anomalies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feroz Shaheen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>SKIMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. WAjid Ali</last_name>
    <role>Study Director</role>
    <affiliation>SKIMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Mushtaq Bhat, MD</last_name>
    <email>mbhat47@rediffmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheri-Kashmir Institute of Medical Sciences</name>
      <address>
        <city>Srinagar</city>
        <state>Jammu and kashmir</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mushtaq Bhat, MD</last_name>
      <email>mbhat47@rediffmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheri Kashmir Institute of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Dr.Mushtaq</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Perinatal asphyxia</keyword>
  <keyword>erythropoietin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asphyxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
